BIB stock forecast, quote, news & analysis

The most notable companies in this group are AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL).

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

The average market capitalization across the ProShares Ultra Nasdaq Biotechnology ETF is 6.88B. The market cap for tickers in the group ranges from 16.66M to 208.98B. AZN holds the highest valuation in this group at 208.98B. The lowest valued company is MRNS at 16.66M.

The average weekly price growth across all stocks in the ProShares Ultra Nasdaq Biotechnology ETF was -20%. For the same ETF, the average monthly price growth was -18%, and the average quarterly price growth was -5%. TSHA experienced the highest price growth at 37%, while RAPT experienced the biggest fall at -62%.

The average weekly volume growth across all stocks in the ProShares Ultra Nasdaq Biotechnology ETF was 13%. For the same stocks of the ETF, the average monthly volume growth was 71% and the average quarterly volume growth was 82%